newsfilter
← Interviews
Milken Institute34 min

A Conversation with Scott Gottlieb, Commissioner, U.S. Food and Drug Administration

Scott Gottlieb, Tanisha Carino, Michael Milken

Fireside Chat, Panel

The FDA is implementing a comprehensive strategic shift to accelerate drug approvals through digital health integration, organizational restructuring within the Office of New Drugs, and a transition to risk-based, post-market regulation for digital tools and manufacturing. This initiative aims to increase review productivity by 20%, publish hundreds of new guidances, and release detailed approval memos within 48 hours to enhance transparency while addressing pipeline disparities in rare versus common diseases. Concurrently, the agency prioritizes tobacco control through modified risk products and fosters market competition to lower drug costs, with Commissioner Gottlieb warning that ossified reimbursement models for novel therapies threaten future innovation if not adapted.